The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The approval comes after a systematic review of published literature
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
Giri stated he is stepping down to pursue new opportunities after careful consideration
Subscribe To Our Newsletter & Stay Updated
